Form 4: Vericel Officer's RSU Vesting and Tax Withholding

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, reported the vesting of Restricted Stock Units and subsequent tax-related share disposals.

Summary

• Jonathan Siegal, Principal Accounting Officer of Vericel Corp, reported transactions related to the vesting of Restricted Stock Units (RSUs).
• On February 24, 2026, 1,540 shares of common stock were acquired due to the vesting of RSUs granted on February 20, 2025.
• Concurrently, 627 shares were disposed of at $38.09 per share to satisfy tax withholding obligations related to this vesting event.
• Additionally, 1,875 shares of common stock were acquired on February 24, 2026, from the vesting of RSUs granted on February 22, 2024.
• 738 shares were disposed of at $38.25 per share for tax withholding purposes related to this second vesting event.
• Following these transactions, Siegal beneficially owns 4,710 shares of common stock directly and 4,620 remaining derivative securities (RSUs from the 2025 grant) and 3,750 remaining derivative securities (RSUs from the 2024 grant).
• The Fair Market Value of the vested derivative securities was $38.09 per share for the 2025 grant and $38.25 per share for the 2024 grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and retention. It does not indicate any significant change in company performance or outlook.

Positives

• The vesting of Restricted Stock Units represents a scheduled component of executive compensation, indicating the retention and incentivization of a key officer.
• The acquisition of common stock through RSU vesting increases the direct equity stake of the Principal Accounting Officer in Vericel Corp.

Negatives

• A portion of the vested shares was disposed of to cover tax withholding requirements, which is a standard practice but results in a reduction of the direct shareholding.

Future Outlook

The remaining Restricted Stock Units granted on February 20, 2025, are scheduled to vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029. The remaining RSUs granted on February 22, 2024, are scheduled to vest in annual installments on February 22, 2027, and February 22, 2028.

Management Comments

• The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted on February 20, 2025, and February 22, 2024.
• Shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of RSUs.

Industry Context

StockSavvy.ai notes that the vesting of Restricted Stock Units and subsequent tax-related share disposals are standard components of executive compensation packages across various industries. This type of transaction is a routine event for publicly traded companies, designed to align executive interests with shareholder value over time.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation is a common practice among U.S. public companies, comparable to compensation structures at peers like Stryker Corporation or Zimmer Biomet Holdings in the medical technology sector, which also utilize performance-based and time-based equity awards.
• The disposition of shares to cover tax obligations upon RSU vesting is a standard and expected event, consistent with practices observed across the S&P 500 for executive compensation plans.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale of shares by an executive is a routine event and generally has minimal direct impact on the broader shareholder base or stock price.
• Employees (specifically Jonathan Siegal): The vesting of RSUs represents a realization of deferred compensation, increasing the executive's direct ownership and personal wealth.

Next Steps

• Future annual vesting installments for RSUs granted on February 20, 2025, are scheduled for February 20, 2027, February 20, 2028, and February 20, 2029.
• Future annual vesting installments for RSUs granted on February 22, 2024, are scheduled for February 22, 2027, and February 22, 2028.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the fundamental investment thesis for Vericel Corp.

Keywords

Vericel, VCEL, Form 4, Restricted Stock Units, RSU vesting, insider transaction, executive compensation, stock ownership